Zvi Ram

Active 1989–2026

75
Papers
19,158
Citations
59
h-index
73
i10-index

Citations

Citations per year for Zvi Ram1966: 1 citations1982: 1 citations1986: 1 citations1992: 4 citations1993: 23 citations1994: 69 citations1995: 77 citations1996: 55 citations1997: 59 citations1998: 55 citations1999: 67 citations2000: 73 citations2001: 30 citations2002: 44 citations2003: 46 citations2004: 55 citations2005: 88 citations2006: 71 citations2007: 88 citations2008: 79 citations2009: 88 citations2010: 98 citations2011: 97 citations2012: 83 citations2013: 108 citations2014: 94 citations2015: 132 citations2016: 121 citations2017: 152 citations2018: 174 citations2019: 605 citations2020: 752 citations2021: 795 citations2022: 546 citations2023: 412 citations2024: 633 citations2025: 284 citations2026: 9 citations1967–1981: no citations, so these years are not shown1983–1985: no citations, so these years are not shown1987–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,014 citing papers, 31% of this breakdownChina: 740 citing papers, 11.4% of this breakdownGermany: 468 citing papers, 7.2% of this breakdownUnited Kingdom: 327 citing papers, 5% of this breakdownItaly: 282 citing papers, 4.4% of this breakdownFrance: 265 citing papers, 4.1% of this breakdownCanada: 195 citing papers, 3% of this breakdownSwitzerland: 187 citing papers, 2.9% of this breakdownJapan: 159 citing papers, 2.5% of this breakdownNetherlands: 156 citing papers, 2.4% of this breakdownIsrael: 139 citing papers, 2.1% of this breakdownSpain: 119 citing papers, 1.8% of this breakdown
0%31%Other 22.2%

Fields

  • Medicine57%
  • Biochemistry, Genetics and Molecular Biology24%
  • Engineering5.8%
  • Immunology and Microbiology4.2%
  • Materials Science3.6%
  • Neuroscience3.2%
  • Other2.2%

Topics

  • Glioma Diagnosis and Treatment15.2%
  • Brain Metastases and Treatment3.9%
  • Virus-based gene therapy research3.1%
  • Nanoparticle-Based Drug Delivery2.3%
  • Nanoplatforms for cancer theranostics2.3%
  • Meningioma and schwannoma management2.2%
  • Other71%

Coauthors

All papers

Open in search
  1. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2017 cited by 2,595

  2. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2015 cited by 1,226

  3. Register allocation: A program-algebraic approach

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey N. Bruce, Rees Cosgrove, Nina Paleologous, Yoram Palti, Philip H. Gutin - European Journal of Cancer 2001 cited by 847

  4. Clinical practice guidelines for the management of adult diffuse gliomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yiwu Dai, Shengqing Lv, Liang Wang, Zhixiong Lin, Jun Dong, Guozheng Xu, Xiaodong Ma, Wei Zhang, Chuanbao Zhang, Baoshi Chen, Gan You, Yongzhi Wang, Yinyan Wang, Zhaoshi Bao, Pei Yang, Xing Fan, Xing Liu, Zheng Zhao, Zheng Wang, Yiming Li, Zhiliang Wang, Guanzhang Li, Shengyu Fang, Lianwang Li, Yanwei Liu, Shuai Liu, Xia Shan, Yuqing Liu, Ruichao Chai, Huimin Hu, Jing Chen, Wei Yan, Jinquan Cai, Hongjun Wang, Lingchao Chen, Yuan Yang, Yu Wang, Lei Han, Qixue Wang - Cancer Letters 2020 cited by 473

  5. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

    Authors: , , , , , , , , - Neuro-Oncology 2003 cited by 1,316

  6. Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment

    Authors: , , , , , , , , , , , , - Science Advances 2021 cited by 176

  7. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

    Authors: , , , , , , , , , , , , , , , , - Neuro-Oncology 2010 cited by 481

  8. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

    Authors: , , , , , , , , , , , , , , - The Lancet Oncology 2014 cited by 755

  9. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 cited by 192

  10. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

    Authors: , , , - Journal of Neuro-Oncology 2018 cited by 176

  11. P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression

    Authors: , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 78

  12. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , - The Lancet Oncology 2013 cited by 240

  13. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study

    Authors: , , , , , - Frontiers in Oncology 2020 cited by 69

  14. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study

    Authors: , , , , , , , - Journal of neurosurgery 2004 cited by 341

  15. Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome

    Authors: , , , , , , , , , , , , , , , , , , - eLife 2017 cited by 99

  16. Altered adenosine-to-inosine RNA editing in human cancer

    Authors: , , , , , , , , , , , , , , , , - Genome Research 2007 cited by 359

  17. MRI radiomics analysis of molecular alterations in low-grade gliomas

    Authors: , , , , , , , , , - International Journal of Computer Assisted Radiology and Surgery, Int. J. Comput. Assist. Radiol. Surg. 2017 cited by 84

  18. The default network is causally linked to creative thinking

    Authors: , , , , , , , , , - Molecular Psychiatry 2022 cited by 61

  19. Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases

    Authors: , , , , , , , , - Journal of Neuro-Oncology 2022 cited by 37

  20. T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields

    Authors: , , , , , , , , , , , - The Journal of Immunology 2021 cited by 28

  21. The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns

    Authors: , , , , , , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2021 cited by 44

  22. Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Cancer 2023 cited by 29

  23. Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100A™ System Versus Best Physician’s Choice Chemotherapy

    Authors: , , , - Seminars in Oncology 2014 cited by 108

  24. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial

    Authors: , , , , , - Frontiers in Oncology 2021 cited by 33